Limberis JT - Search Results

1

Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.

Su Z, Preusser L, Diaz G, Green J, Liu X, Polakowski J, Dart M, Yao B, Meyer M, Limberis JT, Martin RL, Cox BF, Gintant GA. Su Z, et al. Among authors: limberis jt. Curr Drug Saf. 2011 Nov 1;6(5):277-84. doi: 10.2174/157488611798918728. Curr Drug Saf. 2011. PMID: 22424534

2

A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current.

Su Z, Widomski DL, Liu X, Limberis JT, Green J, Diaz G, Martin RL, Cox BF, Gintant GA. Su Z, et al. Among authors: limberis jt. Biochem Pharmacol. 2010 Oct 1;80(7):1000-6. doi: 10.1016/j.bcp.2010.06.006. Epub 2010 Jun 22. Biochem Pharmacol. 2010. PMID: 20599796

3

Functional consequences of methionine oxidation of hERG potassium channels.

Su Z, Limberis J, Martin RL, Xu R, Kolbe K, Heinemann SH, Hoshi T, Cox BF, Gintant GA. Su Z, et al. Biochem Pharmacol. 2007 Sep 1;74(5):702-11. doi: 10.1016/j.bcp.2007.06.002. Epub 2007 Jun 7. Biochem Pharmacol. 2007. PMID: 17624316 Free PMC article.

4

Electrophysiologic characterization of a novel hERG channel activator.

Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, Gintant GA. Su Z, et al. Biochem Pharmacol. 2009 Apr 15;77(8):1383-90. doi: 10.1016/j.bcp.2009.01.015. Epub 2009 Feb 3. Biochem Pharmacol. 2009. PMID: 19426677

5

Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.

Limberis JT, Su Z, Cox BF, Gintant GA, Martin RL. Limberis JT, et al. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1059-65. doi: 10.1111/j.1440-1681.2006.04487.x. Clin Exp Pharmacol Physiol. 2006. PMID: 17042915

6

In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.

Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA. Martin RL, et al. Among authors: limberis jt. J Cardiovasc Pharmacol. 2006 Nov;48(5):199-206. doi: 10.1097/01.fjc.0000246853.15926.d4. J Cardiovasc Pharmacol. 2006. PMID: 17110801

7

The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D, L-sotalol.

Limberis JT, McDermott JS, Salmen HJ, Su Z, Mikhail A, Green JR, Cox BF, Gintant GA, Martin RL. Limberis JT, et al. J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):11-7. doi: 10.1016/j.vascn.2007.01.001. Epub 2007 Feb 12. J Pharmacol Toxicol Methods. 2007. PMID: 17350293

8

Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.

Mikhail A, Fischer C, Patel A, Long MA, Limberis JT, Martin RL, Cox BF, Gintant GA, Su Z. Mikhail A, et al. Among authors: limberis jt. J Cardiovasc Pharmacol. 2007 May;49(5):269-74. doi: 10.1097/FJC.0b013e318036dd05. J Cardiovasc Pharmacol. 2007. PMID: 17513944

9

Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.

Green JR, Diaz GJ, Limberis JT, Houseman KA, Su Z, Martin RL, Cox BF, Kantor S, Gintant GA. Green JR, et al. Among authors: limberis jt. J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):68-73. doi: 10.1016/j.vascn.2011.03.005. Epub 2011 Apr 2. J Pharmacol Toxicol Methods. 2011. PMID: 21440075

10

Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.

Liu X, Limberis JT, Su Z, Houseman K, Diaz GJ, Gintant GA, Cox BF, Martin RL. Liu X, et al. Among authors: limberis jt. Life Sci. 2012 Apr 20;90(15-16):607-11. doi: 10.1016/j.lfs.2012.02.017. Epub 2012 Mar 3. Life Sci. 2012. PMID: 22406079

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters